AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
3.270
-0.180 (-5.22%)
At close: Apr 2, 2026, 4:00 PM EDT
3.150
-0.120 (-3.67%)
After-hours: Apr 2, 2026, 6:53 PM EDT
AN2 Therapeutics Employees
AN2 Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$1,674,952
Market Cap
117.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | -19 | -46.34% | 22 | 0 |
| Dec 31, 2023 | 41 | 5 | 13.89% | 41 | 0 |
| Mar 31, 2023 | 36 | 14 | 63.64% | 35 | 1 |
| Dec 31, 2022 | 36 | 14 | 63.64% | 35 | 1 |
| Sep 30, 2022 | 27 | 5 | 22.73% | 26 | 1 |
| Jun 30, 2022 | 25 | - | - | 25 | 0 |
| Mar 31, 2022 | 22 | - | - | 22 | 0 |
| Dec 31, 2021 | 22 | - | - | 22 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Innate Pharma | 163 |
| Agenus | 81 |
| PepGen | 56 |
| Biomea Fusion | 42 |
| Equillium | 35 |
| Cardiff Oncology | 31 |
| Genelux | 26 |
ANTX News
- 3 days ago - AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease - Business Wire
- 17 days ago - AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 23 days ago - AN2 Therapeutics Stock Cools Off After 90% Rally - Benzinga
- 25 days ago - AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? - Benzinga
- 25 days ago - AN2 Therapeutics Announces $40 Million Private Placement Financing - Business Wire
- 4 weeks ago - AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - Business Wire
- 6 weeks ago - AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference - Business Wire
- 2 months ago - AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease - Business Wire